Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
ACTIVE NOT RECRUITING
NCT03164486
EARLY_PHASE1

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Sponsor: Julie L. Sutcliffe, Ph.D

View on ClinicalTrials.gov

Summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

27

Start Date

2016-11

Completion Date

2026-12

Last Updated

2026-02-27

Healthy Volunteers

No

Conditions

Breast CarcinomaColorectal CarcinomaLung CarcinomaMetastatic Malignant Neoplasm in the BreastMetastatic Malignant Neoplasm in the ColonMetastatic Malignant Neoplasm in the LungMetastatic Malignant Neoplasm in the RectumPancreatic Carcinoma

Interventions

DRUG

18F-αvβ6-BP

Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).

Locations (1)

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States